An interventional study of Ergospirometry in Cancer Therapy-related Cardiovascular Toxicity, Childhood Cancer and Chemotherapeutic Toxicity, sponsored by Centre Hospitalier Universitaire de Liege. Not yet recruiting. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Centre Hospitalier Universitaire de Liege · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this prospective interventional study is to improve the detection of subclinical chronic Cancer Therapy-Related Cardiovascular Toxicity (CTRCT) and evaluate the added value of advanced cardioechography, ergospirometry, and specific biomarkers in pediatric cancer survivors (aged 2 to 25) who received potentially cardiotoxic treatments (chemotherapy/thoracic radiotherapy). The main questions it aims to answer are:
At time of follow-up, if they agree, participants will:
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 100 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Centre Hospitalier Universitaire de Liege is the lead sponsor of 40 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients aged 2 to 25 years followed at CHU de Liège, who have received potentially cardiotoxic treatment (chemotherapy and/or thoracic radiotherapy) for pediatric cancer or bone marrow transplantation since January 1st, 2016 and are in remission for at least 1 year.
Diagnostic Test: Ergospirometry
Completion of validated, age-appropriate quality of life scales and physical activity assessment forms. Patients over 8 years of age will perform a standardized cardiopulmonary exercise test (CPET / ergospirometry) on a treadmill. Seven-day continuous monitoring using a wearable accelerometer. Collection of a 10 mL blood sample (one EDTA tube and one serum-clotting tube), to be centrifuged and stored at -80°C in the CHU de Liège "BHUL" biobank.
Also known as: Accelerometer Data, Biology sample, quality of life and physical activity validated evaluation forms
EKG anomaly
Presence of arrhythmia, prolonged QTc interval, or conduction disorders.
Time frame: At inclusion (single study visit)
Echocardiography anomaly: systolic dysfunction
Systolic dysfunction: LVEF \< 55% or a relative decrease of \>15%.
Time frame: At inclusion (single study visit)
Echocardiography anomaly: diastolic dysfunction
Based on standardized pediatric values : * E/A ratioaverage * E/e' \> 14 * e' velocities * LA volume index \> 32 mL/m².
Time frame: At inclusion (single study visit)
Echocardiography anomaly: Significant alteration in myocardial deformation
GLS decrease \> 15%
Time frame: At inclusion (single study visit)
Echocardiography anomaly: myocardial work indices
abnormal Myocardial Work indices
Time frame: At inclusion (single study visit)
Echocardiography anomaly: valvular disease or heart inflammation
Structural/Inflammatory damage: Significant valvular disease, or signs of acute/chronic pericarditis and myocarditis.
Time frame: At inclusion (single study visit)
Cardiopulmonary Exercise Testing (CPET): Impaired functional capacity
defined as peak VO2 \< 85% or maximal workload \< 85% of predicted theoretical values.
Time frame: At inclusion (single study visit)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Dec 2028, 34 months later.
Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 34 months is above that.
Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Liege